1794767-04-6

1794767-04-6 structure

Name: Ruboxistaurin-d6 hydrochloride
Chemical Name: Ruboxistaurin-d6 hydrochloride
CAS Number: 1794767-04-6
Molecular Formula: C₂₈H₂₃D₆ClN₄O₃
Molecular Weight: 511.04
Catalog: Signaling Pathways Epigenetics PKC
Create Date: 2021-10-25 14:27:47
Modify Date: 2024-01-15 07:25:27
Ruboxistaurin-d6 (LY333531-d6) hydrochloride is the deuterium labeled Ruboxistaurin hydrochloride. Ruboxistaurin (LY333531) hydrochloride is an orally active, selective PKC beta inhibitor (Ki=2 nM). Ruboxistaurin hydrochloride exhibits ATP dependent competitive inhibition of PKC beta I with an IC50 of 4.7 nM. Ruboxistaurin hydrochloride inhibits PKC beta II with an IC50 of 5.9 nM[1][2].

Name	Ruboxistaurin-d6 hydrochloride

Description	Ruboxistaurin-d6 (LY333531-d6) hydrochloride is the deuterium labeled Ruboxistaurin hydrochloride. Ruboxistaurin (LY333531) hydrochloride is an orally active, selective PKC beta inhibitor (Ki=2 nM). Ruboxistaurin hydrochloride exhibits ATP dependent competitive inhibition of PKC beta I with an IC50 of 4.7 nM. Ruboxistaurin hydrochloride inhibits PKC beta II with an IC50 of 5.9 nM[1][2].
Related Catalog	Signaling Pathways >> Epigenetics >> PKC Research Areas >> Metabolic Disease Signaling Pathways >> TGF-beta/Smad >> PKC
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Jirousek MR, et al. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J Med Chem. 1996;39(14):2664-2671. [3]. Ruboxistaurin: LY 333531. Drugs R D. 2007;8(3):193-199. [4]. Kunt T, et al. The beta-specific protein kinase C inhibitor ruboxistaurin (LY333531) suppresses glucose-induced adhesion of human monocytes to endothelial cells in vitro. J Diabetes Sci Technol. 2007 Nov;1(6):929-35. [5]. Nonaka A, et al. PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2702-6.

Molecular Formula	C₂₈H₂₃D₆ClN₄O₃
Molecular Weight	511.04

1794767-04-6	169939-93-9
1217229-05-4	1795020-86-8
2748492-38-6	1346601-02-2
2517378-96-8	2748541-96-8
1089675-56-8	1181578-71-1